Drug intelligence / Profile preview

Eribaxaban

Development stage: Phase 2
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

Eribaxaban is an orally active small molecule anticoagulant that acts as a selective and direct inhibitor of coagulation factor Xa. By inhibiting factor Xa, it disrupts the coagulation cascade and prevents thrombin formation and clot development. Eribaxaban was developed by Pfizer for the treatment and prevention of thrombotic disorders such as venous thrombosis. It reached phase II clinical trials but development was discontinued before approval or marketing[1][3][5][7].

Other names: eribaxaban

Targets

F10 (Factor Xa)

Beyond the preview

Go deeper on Eribaxaban.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eribaxaban.

Explore the full profile